Successful Treatment of Cryoglobulinaemia with Rituximab

Overview

Journal Case Rep Nephrol Urol

Specialty Nephrology

Date 2012 Dec 1

PMID 23197959

Citations 2

Authors

M Choudhry

N Rao

R Juneja

Affiliations

Soon will be listed here.

Abstract

Cryoglobulinaemia is a systemic inflammatory condition characterised by immune complex-mediated small-to-medium-sized vasculitis. It has a wide variety of presentations ranging from bruising, neuropathy, and hepatosplenomegaly to acute renal failure. Mixed cryoglobulinaemia is the most common type and is strongly associated with hepatitis C. Management approaches include use of cyclophosphamide, prednisolone, and plasmapheresis, with differing views on alternative treatments in resistant cases. Rituximab has emerged as an attractive option in resistant cases on account of its potent immunosuppressive effects on B cells. We describe a case of type 2 mixed cryoglobulinaemia in association with non-Hodgkin's lymphoma resistant to standard treatments which responded well to rituximab. This case is remarkable as mixed cryoglobulinaemia associated with non-Hodgkin's lymphoma presenting with nephritis is unusual, and, contrary to the high rate of recurrence in lymphoma-related cryoglobulinaemia, our patient has not shown any recurrence over 24 months. This highlights an alternative treatment modality which can be used in patients not responsive to existing managements for this condition with benefits of minimal side effects and no oncogenetic potential.

Citing Articles

Recurrent localized fever caused by cryoglobulinemic vasculitis following hemodialysis: A case report.

Kojima M, Shibata M, Tomita S, Ueda R, Kasai R, Yamamoto E CEN Case Rep. 2024; .

PMID: 39102128 DOI: 10.1007/s13730-024-00923-w.

Rituximab therapy for primary glomerulonephritis: Report on two cases.

Fabrizi F, Cresseri D, Fogazzi G, Moroni G, Passerini P, Martin P World J Clin Cases. 2015; 3(8):736-42.

PMID: 26301235 PMC: 4539414. DOI: 10.12998/wjcc.v3.i8.736.

References

Monti G, Galli M, Invernizzi F, Pioltelli P, Saccardo F, Monteverde A . Cryoglobulinaemias: a multi-centre study of the early clinical and laboratory manifestations of primary and secondary disease. GISC. Italian Group for the Study of Cryoglobulinaemias. QJM. 1995; 88(2):115-26. View

Cicardi M, Cesana B, Del Ninno E, Pappalardo E, Silini E, AGOSTONI A . Prevalence and risk factors for the presence of serum cryoglobulins in patients with chronic hepatitis C. J Viral Hepat. 2000; 7(2):138-43. DOI: 10.1046/j.1365-2893.2000.00204.x. View

Roccatello D, Baldovino S, Rossi D, Giachino O, Mansouri M, Naretto C . Rituximab as a therapeutic tool in severe mixed cryoglobulinemia. Clin Rev Allergy Immunol. 2008; 34(1):111-7. DOI: 10.1007/s12016-007-8019-0. View

Terrier B, Launay D, Kaplanski G, Hot A, Larroche C, Cathebras P . Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: data from the French Autoimmunity and Rituximab registry. Arthritis Care Res (Hoboken). 2010; 62(12):1787-95. DOI: 10.1002/acr.20318. View

Maloney D, Grillo-Lopez A, White C, Bodkin D, Schilder R, Neidhart J . IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 1997; 90(6):2188-95. View

Kishore D, Misra S . Cryoglobulinemia presenting as acute polyneuropathy. J Assoc Physicians India. 2009; 56:998-9. View

Ramos-Casals M, Garcia-Hernandez F, de Ramon E, Callejas J, Martinez-Berriotxoa A, Pallares L . Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. Clin Exp Rheumatol. 2010; 28(4):468-76. View

Pfreundschuh M, Kuhnt E, Trumper L, Osterborg A, Trneny M, Shepherd L . CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011; 12(11):1013-22. DOI: 10.1016/S1470-2045(11)70235-2. View

Matignon M, Cacoub P, Colombat M, Saadoun D, Brocheriou I, Mougenot B . Clinical and morphologic spectrum of renal involvement in patients with mixed cryoglobulinemia without evidence of hepatitis C virus infection. Medicine (Baltimore). 2009; 88(6):341-348. DOI: 10.1097/MD.0b013e3181c1750f. View

10.

Zaja F, De Vita S, Mazzaro C, Sacco S, Damiani D, De Marchi G . Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood. 2003; 101(10):3827-34. DOI: 10.1182/blood-2002-09-2856. View

11.

Sinico R, Winearls C, Sabadini E, Fornasieri A, Castiglione A, DAmico G . Identification of glomerular immune deposits in cryoglobulinemia glomerulonephritis. Kidney Int. 1988; 34(1):109-16. DOI: 10.1038/ki.1988.152. View

12.

Baronciani D, Angelucci E, Gaziev J, Visani G . Inefficacy of rituximab in a case of low grade non-Hodgkin's lymphoma with cryoglobulinemia. Haematologica. 2002; 87(7):ELT33. View

13.

Foessel L, Besancenot J, Blaison G, Magy-Bertrand N, Jaussaud R, Etienne Y . Clinical spectrum, treatment, and outcome of patients with type II mixed cryoglobulinemia without evidence of hepatitis C infection. J Rheumatol. 2011; 38(4):716-22. DOI: 10.3899/jrheum.100898. View

14.

Bryce A, Dispenzieri A, Kyle R, Lacy M, Rajkumar S, Inwards D . Response to rituximab in patients with type II cryoglobulinemia. Clin Lymphoma Myeloma. 2006; 7(2):140-4. DOI: 10.3816/CLM.2006.n.052. View

15.

Reff M, Carner K, Chambers K, Chinn P, Leonard J, Raab R . Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994; 83(2):435-45. View

16.

Tarantino A, Campise M, Banfi G, Confalonieri R, Bucci A, Montoli A . Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis. Kidney Int. 1995; 47(2):618-23. DOI: 10.1038/ki.1995.78. View

17.

Sailler L . Rituximab off label use for difficult-to-treat auto-immune diseases: reappraisal of benefits and risks. Clin Rev Allergy Immunol. 2008; 34(1):103-10. DOI: 10.1007/s12016-007-8020-7. View